Diagnostic accuracy evaluation of the ImmunoFlow HCV rapid immunochromatographic test for the detection of hepatitis C antibodies

Journal of Virological Methods

Volumn 204, Issue , 2014, Pages 6-10

  Kosack, Cara S ^a   Nick, Sigrid ^b   Shanks, Leslie ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Diagnostic; HCV; Hepatitis C; ImmunoFlow; Rapid diagnostic test; RDT

Indexed keywords

HEPATITIS C ANTIBODY;

ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; GERMANY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; BLOOD; DIAGNOSTIC PROCEDURE; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; PROCEDURES;

CLINICAL LABORATORY TECHNIQUES; GERMANY; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOCHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 84899546172     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.03.012     Document Type: Article

References (42)

1. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int. J. Drug Policy 2007, 18:352-358.
2. Alter M.J. Epidemiology of hepatitis C virus infection. World. J. Gastroenterol. 2007, 13:2436-2441.
3. Alter M.J., Kuhnert W.L., Finelli L., Centers for Disease Control and Prevention Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm. Rep. 2003, 52(RR-3). 1-13, 15; quiz CE1-4. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5203a1.htm.
4. Averhoff F.M., Glass N., Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin. Infect. Dis. 2012, 55(July (Suppl. 1)):S10-S15.
5. Bonacini M., Lin H.J., Hollinger F.B. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J. Acquir. Immune Defic. Syndr. 2011, 26:340-344.
6. Busch M.P., Kleinman S.H., Nemo G.J. Current and emerging infectious risks of blood transfusions. J. Am. Med. Assoc. 2003, 289:959-963.
7. Candotti D., Sarkodie F., Allain J.P. Residual risk of transfusion in Ghana. Br. J. Haematol. 2001, 113:37-39.
8. Centers for Disease Control and Prevention Testing for HCV infection: an update of guidance for clinicians and laboratorians. Morb. Mortal. Wkly. Rep. 2013, 62(18):362-365. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6218a5.htm%3Fs_cid=mm6218a5_w.
9. Core Diagnostics ImmunoFlow HCV CE. Package insert. Version: Eng 03-05/2008 2008, http://corediag.com/images/ImmunoFlow_HCV-_Pack_Insert-_CE_version_03.pdf.
10. Cornberg M., Razavi H.A., Alberti A., Bernasconi E., Buti M., Cooper C., Dalgard O., Dillion J.F., Flisiak R., Forns X., Frankova S., Goldis A., Goulis I., Halota W., Hunyady B., Lagging M., Largen A., Makara M., Manolakopoulos S., Marcellin P., Marinho R.T., Pol S., Poynard T., Puoti M., Sagalova O., Sibbel S., Simon K., Wallace C., Young K., Yurdaydin C., Zuckerman E., Negro F., Zeuzem S. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011, 31(Suppl. 2):30-60.
11. Dal Molin G., D'Agaro P., Ansaldi F., Ciana G., Fertz C., Alberico S., Campello C. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J. Med. Virol. 2002, 67:137-142.
12. England K., Thorne C., Pembrey L., Newell M.L. Policies and practices for the clinical management of HIV/HCV coinfected children in Europe: an epidemiological survey. Eur. J. Pediatr. 2009, 168(8):915-917.
13. Ferrero S., Lungaro P., Bruzzone B.M., Gotta C., Bentivoglio G., Ragni N. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta. Obstet. Gynecol. Scand. 2003, 82:229-234.
14. Gibb D.M., Goodall R.L., Dunn D.T., Healy M., Neave P., Cafferkey M., Butler K. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000, 356:904-907.
15. Hauri A.M., Armstrong G.L., Hutin Y. The global burden of disease attributable to contaminated injections given in health care settings. Int. J. STD AIDS 2004, 15:7-16.
16. Health Protection Agency An Assessment of the Seroconversion Sensitivity of ImmunoFlow HCV Rapid Test Device (Core Diagnostics). Report PER 06010 2007, http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317133423989.
17. Kamili S., Drobeniuc J., Araujo A.C., Hayden T.M. Laboratory diagnostics for hepatitis C virus infection. Clin. Infect. Dis. 2012, 55(Suppl. 1):S43-S48.
18. Kershenobich D., Razavi H.A., Sánchez-Avila J.F., Bessone F., Coelho H.S., Dagher L., Gonçales F.L., Quiroz J.F., Rodriguez-Perez F., Rosado B., Wallace C., Negro F., Silva M. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int. 2011, 31(Suppl. 2):S18-S29.
19. Madhava V., Burgess C., Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect. Dis. 2002, 2:293-302.
20. Marcellin P., Martinot-Peignoux M., Elias A., Branger M., Courtois F., Level R., Erlinger S., Benhamou J.P. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J. Infect. Dis. 1994, 170:433-435.
21. MSF (Médecins sans Frontières) - Access Campaign Hepatitis C. Diagnosis and Treatment Technical Landscape 2013, http://www.msfaccess.org/sites/default/files/MSF_assets/HepC/Docs/HepC_Report_DxTxTech_ENG_2013_FINAL.pdf.
22. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583.
23. O'Connell R.J., Gates R.G., Bautista C.T., Imbach M., Eggleston J.C., Beardsley S.G., Manak M.M., Gonzales R., Rentas F.J., Macdonald V.W., Cardo L.J., Reiber D.T., Stramer S.L., Michael N.L., Peel S.A. Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings. Transfusion 2013, 53(March (3)):505-517.
24. Operskalski E.A., Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr. HIV/AIDS Rep. 2011, 8:12-22.
25. Peeling R.W., Mabey D. Point-of-care tests for diagnosing infections in the developing world. Clin. Microbiol. Inf. 2010, 16:1062-1069.
26. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006, 45(October (4)):529-538.
27. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J. Hepatol. 2006, 45:607-616.
28. Qureshi H., Bile K.M., Jooma R., Alam S.E., Afridi H.U.R. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East. Mediterr. Health J. 2010, 16(Suppl):S15.
29. Shan H., Wang J.X., Ren F.R., Zhang Y.Z., Zhao H.Y., Gao G.J., Ji Y., Ness P.M. Blood banking in China. Lancet 2002, 360:1770-1775.
30. Shepard C.W., Finelli L., Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
31. Shivkumar S., Peeling R., Jafari Y., Joseph L., Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C. A systematic review and meta-analysis. Ann. Intern. Med. 2012, 157:558-566.
32. Sievert W., Altraif I., Razavi H.A., Abdo A., Ahmed E.A., Alomair A., Amarapurkar D., Chen C.H., Dou X., El Khayat H., Elshazly M., Esmat G., Guan R., Han K.H., Koike K., Largen A., McCaughan G., Mogawer S., Monis A., Nawaz A., Piratvisuth T., Sanai F.M., Sharara A.I., Sibbel S., Sood A., Suh D.J., Wallace C., Young K., Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011, 31(Suppl. 2):61-80.
33. Smith B.D., Teshale E., Jewett A., Weinbaum C.M., Neaigus A., Hagan H., Jenness S.M., Melville S.K., Burt R., Thiede H., Al-Tayyib A., Pannala P.R., Miles I.W., Oster A.M., Smith A., Finlayson T., Bowles K.E., Dinenno E.A. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin. Infect. Dis. 2011, 53(October (8)):780-786.
34. Smith B.D., Drobeniuc J., Jewett A., Branson B.M., Garfein R.S., Teshale E., Kamili S., Weinbaum C.M. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J. Infect. Dis. 2011, 204(September (6)):825-831.
35. WHO Hepatitis C Assays: Operational Characteristics (Phase 1) Report 1, January 2001. WHO/BCT/BTS/01.2 2001, http://www.who.int/diagnostics_laboratory/evaluations/en/hcv_rep1.pdf.
36. WHO Hepatitis C Assays: Operational Characteristics (Phase 1) Report 2, January 2001. WHO/BCT/BTS/01.5 2001.
37. WHO Global Blood Safety and Availability: Key, Facts and Figures. Based on Data from the WHO Global Database on Blood Safety, 2008 2010, http://www.who.int/worldblooddonorday/media/Global_Blood_Safety_and_Availability_Key_facts_figures_2010.pdf.
38. WHO Hepatitis C. Fact sheet N°164 2013, http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
39. WHO Global Policy Report on the Prevention and Control of Viral Hepatitis in WHO Member States 2013, http://apps.who.int/iris/bitstream/10665/85397/1/9789241564632_eng.pdf.
40. WHO HIV/AIDS Programme. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach 2013, http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
41. World Hepatitis Alliance Viral Hepatitis: Global Policy 2011, World Hepatitis Alliance, London.
42. Yeung L.T.F., King S.M., Roberts E.A. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001, 34:223-229.